Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Ionis Pharmaceuticals, Inc.”

202 pharma patents match "Ionis Pharmaceuticals, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 202
Index total 30,257
Page 8 / 9

Quick answer

This filtered view shows 202 pharmaceutical patents matching "Ionis Pharmaceuticals, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

202 results for “Ionis Pharmaceuticals, Inc.” · 30,257 patents in full index Clear search

  1. US 9677076

    Modulation of hepatitis B virus (HBV) expression

    Ionis Pharmaceuticals, Inc. · Granted Jun 13, 2017 · Expires Jun 8, 2037

    granted
  2. US 9670492

    Modulation of prekallikrein (PKK) expression

    Ionis Pharmaceuticals, Inc. · Granted Jun 6, 2017 · Expires Jun 1, 2037

    granted
  3. US 9663783

    Modulation of alpha synuclein expression

    Ionis Pharmaceuticals, Inc. · Granted May 30, 2017 · Expires May 25, 2037

    granted
  4. US 9650636

    Methods for treating hypercholesterolemia

    Ionis Pharmaceuticals, Inc. · Granted May 16, 2017 · Expires May 11, 2037

    granted
  5. US 9644207

    Compositions and methods for modulating Tau expression

    Ionis Pharmaceuticals, Inc. · Granted May 9, 2017 · Expires May 4, 2037

    granted
  6. US 9624496

    Modulation of apolipoprotein C-III expression

    Ionis Pharmaceuticals, Inc. · Granted Apr 18, 2017 · Expires Apr 13, 2037

    granted
  7. US 9617539

    Modulation of UBE3A-ATS expression

    Ionis Pharmaceuticals, Inc. · Granted Apr 11, 2017 · Expires Apr 6, 2037

    granted
  8. US 9617540

    Compounds and methods for modulating gene expression

    Ionis Pharmaceuticals, Inc. · Granted Apr 11, 2017 · Expires Apr 6, 2037

    granted
  9. US 9605259

    Compounds and methods for modulating protein expression

    Ionis Pharmaceuticals, Inc. · Granted Mar 28, 2017 · Expires Mar 23, 2037

    granted
  10. US 9605263

    Compositions for modulating C9ORF72 expression

    Ionis Pharmaceuticals, Inc. · Granted Mar 28, 2017 · Expires Mar 23, 2037

    granted
  11. US 9598693

    Oligomeric compounds and compositions for the use in modulation of micrornas

    Ionis Pharmaceuticals, Inc. · Granted Mar 21, 2017 · Expires Mar 16, 2037

    granted
  12. US 9593333

    Modulation of apolipoprotein C-III (ApoCIII) expression in lipoprotein lipase deficient (LPLD) populations

    Ionis Pharmaceuticals, Inc. · Granted Mar 14, 2017 · Expires Mar 9, 2037

    granted
  13. US 9574193

    Methods and compositions for modulating apolipoprotein (a) expression

    Ionis Pharmaceuticals, Inc. · Granted Feb 21, 2017 · Expires Feb 16, 2037

    granted
  14. US 9567588

    Modulation of androgen receptor expression

    Ionis Pharmaceuticals, Inc. · Granted Feb 14, 2017 · Expires Feb 9, 2037

    granted
  15. US 9567587

    Antisense modulation of GCCR expression

    Ionis Pharmaceuticals, Inc. · Granted Feb 14, 2017 · Expires Feb 9, 2037

    granted
  16. US 9550988

    Antisense compounds

    Ionis Pharmaceuticals, Inc. · Granted Jan 24, 2017 · Expires Jan 19, 2037

    granted
  17. US 9546368

    Methods for modulating metastasis-associated-in-lung-adenocarcinoma-transcript-1 (MALAT-1) expression

    Ionis Pharmaceuticals, Inc. · Granted Jan 17, 2017 · Expires Jan 12, 2037

    granted
  18. US 9540641

    Cancer treatment

    Ionis Pharmaceuticals, Inc. · Granted Jan 10, 2017 · Expires Jan 5, 2037

    granted
  19. US 9523094

    Methods of treating kennedy's disease

    Ionis Pharmaceuticals, Inc. · Granted Dec 20, 2016 · Expires Dec 15, 2036

    granted
  20. US 9518259

    Compounds and methods for modulating interaction between proteins and target nucleic acids

    Ionis Pharmaceuticals, Inc. · Granted Dec 13, 2016 · Expires Dec 8, 2036

    granted
  21. US 9487780

    Antisense compounds targeting genes associated with fibronectin

    Ionis Pharmaceuticals, Inc. · Granted Nov 8, 2016 · Expires Nov 3, 2036

    granted
  22. US 9476051

    Antisense modulation of superoxide dismutase 1, soluble expression

    Ionis Pharmaceuticals, Inc. · Granted Oct 25, 2016 · Expires Oct 20, 2036

    granted
  23. US 9428750

    Oligomeric compounds comprising tricyclic nucleosides and methods for their use

    Ionis Pharmaceuticals, Inc. · Granted Aug 30, 2016 · Expires Aug 25, 2036

    granted
  24. US 9409934

    Cyclohexenyl nucleic acids analogs

    Ionis Pharmaceuticals, Inc. · Granted Aug 9, 2016 · Expires Aug 4, 2036

    granted